Clinical Trial

Tunlametinib + AG + Cetuximab β as First-Line Therapy for Advanced Pancreatic Cancer

Name: Tunlametinib + AG + Cetuximab β as First-Line Therapy for Advanced Pancreatic Cancer — clinical trial record (NCT07302841)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 4

View on ClinicalTrials.gov →

Summary

This study is a prospective, open-label, single-arm clinical trial evaluating the safety and efficacy of tunlametinib in combination with gemcitabine/albumin-bound paclitaxel and an EGFR monoclonal antibody as first-line therapy in treatment-naive subjects with advanced pancreatic cancer.

Trial Details

NCT Number	NCT07302841
Lead Sponsor	Tianjin Medical University Cancer Institute and Hospital
Conditions	Pancreatic Cancer Non-resectable
Enrollment	28 participants
Start Date	2026-01-20
Primary Completion	2027-06-20 (estimated)
Study Completion	2028-12-30 (estimated)
Updated on ClinicalTrials.gov	2025-12-24